Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Koen De GeestWilliam E Richards

Abstract

PURPOSE Ixabepilone (BMS-247550) is a microtubule-stabilizing epothilone B analog with activity in taxane-resistant metastatic breast cancer. The Gynecologic Oncology Group conducted a phase II evaluation of the efficacy and safety of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant primary ovarian or peritoneal carcinoma. PATIENTS AND METHODS Patients with measurable platinum- and taxane-resistant ovarian or peritoneal carcinoma, defined as progression during or within 6 months of one prior course of treatment with each agent, received intravenous ixabepilone 20 mg/m(2) administered over 1 hour on days 1, 8, and 15 of a 28-day cycle. Results Of 51 patients entered, 49 were eligible. The objective response rate was 14.3% (95% CI, 5.9% to 27.2%), with three complete and four partial responses. Twenty patients (40.8%) had stable disease, whereas sixteen (32.7%) had increasing disease. The median time to progression was 4.4 months (95% CI, 0.8 to 32.6+ months); median survival was 14.8 months (95% CI, 0.8 to 50.0) months. Patients received a median of two treatment cycles (range, 1 to 29 cycles), and 18.4% of patients received > or = six cycles. Adverse effects included peripheral grade 2 (28.5%)...Continue Reading

References

Nov 20, 1998·Statistics in Medicine·T T Chen, T H Ng
Nov 9, 2001·Drug Discovery Today·Lifeng HeSusan Band Horwitz
Feb 24, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sridhar ManiSusan Band Horwitz
Mar 9, 2004·The Lancet Oncology·Helen K BerriemanLynn Cawkwell
Apr 3, 2004·Cancer Research·Tamotsu SudoNaoto T Ueno
May 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Susan GoodinEric H Rubin
Apr 22, 2006·Cell Cycle·Charles SwantonJulian Downward
May 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gabriella FerrandinaCristiano Ferlini
Sep 5, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Tristan M SissungStephan Mielke
Jan 31, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carol AghajanianOwen A O'Connor
Jul 4, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neelima DenduluriSandra M Swain
Jul 4, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henri RochéHervé Curé
Jul 4, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Johan VansteenkisteMark Edelman
Jul 4, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezGabriel N Hortobagyi
Jul 4, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eva ThomasMiguel Martin
Dec 21, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sen H ZhuangMarianne S Poruchynsky
Mar 28, 2008·Expert Opinion on Investigational Drugs·Michelle Harrison, Charles Swanton
May 2, 2008·Expert Opinion on Investigational Drugs·Robert O Carlson
May 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sanjay GoelSridhar Mani
Jul 23, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S GoelS Mani
Dec 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·José BaselgaSusan Galbraith

❮ Previous
Next ❯

Citations

Nov 18, 2010·Archives of Gynecology and Obstetrics·Ansgar Brüning, Ioannis Mylonas
Oct 5, 2010·Nature Reviews. Drug Discovery·Charles Dumontet, Mary Ann Jordan
Oct 15, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A Bookman
Oct 15, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J A Ledermann, R S Kristeleit
Sep 26, 2013·Journal of the National Cancer Institute·Christina M Annunziata, Elise C Kohn
Jul 27, 2011·Therapeutic Advances in Medical Oncology·Francis LeeMark E Salvati
Oct 12, 2010·The Oncologist·Katherine M Moxley, D Scott McMeekin
Apr 6, 2011·Future Oncology·Ivan Diaz-Padilla, Amit M Oza
Sep 18, 2013·Gynecologic Oncology·Katrina N SlaughterKathleen N Moore
Oct 28, 2010·Medical Oncology·Ellen B KossoffTracey L O'Connor
Nov 3, 2011·Current Oncology Reports·Marcia Hall, Gordon Rustin
Sep 8, 2010·Expert Opinion on Investigational Drugs·Koji MatsuoAnil K Sood
Nov 10, 2012·Critical Reviews in Oncology/hematology·Bradley J MonkIvor Benjamin
Apr 24, 2012·Hematology/oncology Clinics of North America·Susana M Campos, Don S Dizon
May 31, 2011·Gynecologic Oncology·Ilenia PellicciottaShohreh Shahabi
Oct 21, 2015·Analytical Cellular Pathology (Amsterdam)·Daniele FanaleViviana Bazan
Jun 6, 2012·Gynecologic Oncology·Keith C BibleUNKNOWN North Central Cancer Treatment Group (NCCTG)
Oct 12, 2010·Cancer Biology & Therapy·Tetyana V BagnyukovaIgor Astsaturov
Sep 6, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·David R SpigelJohn D Hainsworth
Jan 24, 2017·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Concetta LalisciaAngiolo Gadducci
Dec 25, 2012·Expert Review of Anticancer Therapy·Diana P EnglishAlessandro D Santin
Feb 22, 2012·Clinical Obstetrics and Gynecology·Leigh G SeamonLarry J Copeland
May 20, 2017·Expert Opinion on Pharmacotherapy·Federica TomaoPierluigi Benedetti Panici
Aug 25, 2017·Expert Opinion on Emerging Drugs·Paola Claudia Sacco, Cesare Gridelli
Feb 1, 2017·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Concetta LalisciaAngiolo Gadducci
Jun 5, 2021·Expert Opinion on Investigational Drugs·Shuk On Annie Leung, Panagiotis A Konstantinopoulos
Dec 31, 2010·Current Opinion in Obstetrics & Gynecology

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Don S DizonRonald D Alvarez
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Gabriella FerrandinaCristiano Ferlini
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Sridhar ManiS B Horwitz
Annals of Oncology : Official Journal of the European Society for Medical Oncology
P FumoleauE Ferrant
© 2022 Meta ULC. All rights reserved